Stryker Gross Margin 2010-2025 | SYK
Current and historical gross margin for Stryker (SYK) over the last 10 years. The current gross profit margin for Stryker as of March 31, 2025 is %.
| Stryker Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2025-03-31 | $23.22B | $14.85B | 63.96% |
| 2024-12-31 | $22.60B | $14.44B | 63.91% |
| 2024-09-30 | $21.97B | $13.97B | 63.57% |
| 2024-06-30 | $21.39B | $13.61B | 63.63% |
| 2024-03-31 | $20.96B | $13.38B | 63.80% |
| 2023-12-31 | $20.50B | $13.06B | 63.70% |
| 2023-09-30 | $19.89B | $12.59B | 63.32% |
| 2023-06-30 | $19.46B | $12.22B | 62.79% |
| 2023-03-31 | $18.95B | $11.86B | 62.58% |
| 2022-12-31 | $18.45B | $11.58B | 62.76% |
| 2022-09-30 | $17.95B | $11.39B | 63.44% |
| 2022-06-30 | $17.63B | $11.25B | 63.80% |
| 2022-03-31 | $17.43B | $11.19B | 64.22% |
| 2021-12-31 | $17.11B | $10.97B | 64.11% |
| 2021-09-30 | $16.67B | $10.64B | 63.83% |
| 2021-06-30 | $16.25B | $10.46B | 64.38% |
| 2021-03-31 | $14.72B | $9.24B | 62.75% |
| 2020-12-31 | $14.35B | $9.06B | 63.11% |
| 2020-09-30 | $14.22B | $9.04B | 63.59% |
| 2020-06-30 | $14.07B | $8.91B | 63.34% |
| 2020-03-31 | $14.96B | $9.74B | 65.15% |
| 2019-12-31 | $14.88B | $9.70B | 65.14% |
| 2019-09-30 | $14.55B | $9.45B | 64.95% |
| 2019-06-30 | $14.20B | $9.27B | 65.29% |
| 2019-03-31 | $13.88B | $9.08B | 65.47% |
| 2018-12-31 | $13.60B | $8.94B | 65.72% |
| 2018-09-30 | $13.28B | $8.72B | 65.71% |
| 2018-06-30 | $13.04B | $8.55B | 65.58% |
| 2018-03-31 | $12.73B | $8.35B | 65.62% |
| 2017-12-31 | $12.44B | $8.18B | 65.73% |
| 2017-09-30 | $12.13B | $8.03B | 66.23% |
| 2017-06-30 | $11.96B | $7.92B | 66.26% |
| 2017-03-31 | $11.79B | $7.77B | 65.97% |
| 2016-12-31 | $11.33B | $7.50B | 66.26% |
| 2016-09-30 | $10.88B | $7.23B | 66.42% |
| 2016-06-30 | $10.47B | $6.98B | 66.67% |
| 2016-03-31 | $10.06B | $6.74B | 67.01% |
| 2015-12-31 | $9.95B | $6.60B | 66.38% |
| 2015-09-30 | $9.85B | $6.50B | 66.01% |
| 2015-06-30 | $9.82B | $6.44B | 65.56% |
| 2015-03-31 | $9.75B | $6.38B | 65.44% |
| 2014-12-31 | $9.68B | $6.36B | 65.70% |
| 2014-09-30 | $9.53B | $6.23B | 65.39% |
| 2014-06-30 | $9.29B | $6.14B | 66.08% |
| 2014-03-31 | $9.14B | $6.07B | 66.45% |
| 2013-12-31 | $9.02B | $6.02B | 66.72% |
| 2013-09-30 | $8.89B | $6.02B | 67.72% |
| 2013-06-30 | $8.79B | $5.95B | 67.66% |
| 2013-03-31 | $8.69B | $5.90B | 67.94% |
| 2012-12-31 | $8.66B | $5.88B | 67.88% |
| 2012-09-30 | $8.53B | $5.76B | 67.47% |
| 2012-06-30 | $8.51B | $5.72B | 67.23% |
| 2012-03-31 | $8.45B | $5.62B | 66.51% |
| 2011-12-31 | $8.31B | $5.50B | 66.16% |
| 2011-09-30 | $8.09B | $5.39B | 66.66% |
| 2011-06-30 | $7.82B | $5.26B | 67.18% |
| 2011-03-31 | $7.54B | $5.14B | 68.23% |
| 2010-12-31 | $7.32B | $5.03B | 68.77% |
| 2010-09-30 | $7.16B | $4.91B | 68.52% |
| 2010-06-30 | $7.04B | $4.79B | 68.04% |
| 2010-03-31 | $6.92B | $4.67B | 67.51% |
| 2009-12-31 | $6.72B | $4.54B | 67.54% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $145.454B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.365B | 28.30 |
| Boston Scientific (BSX) | United States | $147.057B | 36.81 |
| EssilorLuxottica (ESLOY) | France | $130.907B | 0.00 |
| Medtronic (MDT) | Ireland | $112.941B | 16.01 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.659B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.106B | 27.97 |
| ResMed (RMD) | United States | $36.856B | 27.68 |
| Agilent Technologies (A) | United States | $34.008B | 22.17 |
| GE HealthCare Technologies (GEHC) | United States | $33.609B | 15.96 |
| Terumo (TRUMY) | Japan | $26.946B | 35.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.201B | 15.96 |
| Insulet (PODD) | United States | $21.270B | 83.49 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.645B | 11.98 |
| Baxter (BAX) | United States | $16.114B | 12.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.196B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.264B | 21.80 |
| Lantheus Holdings (LNTH) | United States | $5.587B | 14.09 |
| Prestige Consumer Healthcare (PBH) | United States | $4.206B | 18.79 |
| Perrigo (PRGO) | Ireland | $3.763B | 9.54 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.435B | 15.65 |
| ICU Medical (ICUI) | United States | $3.309B | 24.40 |
| Envista Holdings (NVST) | United States | $3.259B | 27.08 |
| GN Store Nord (GNNDY) | Denmark | $2.362B | 19.57 |
| QuidelOrtho (QDEL) | United States | $2.094B | 14.40 |
| LeMaitre Vascular (LMAT) | United States | $1.878B | 41.99 |
| AtriCure (ATRC) | United States | $1.635B | 0.00 |
| Acuren (TIC) | United States | $1.305B | 0.00 |
| Neogen (NEOG) | United States | $1.238B | 15.85 |
| AdaptHealth (AHCO) | United States | $1.181B | 11.99 |
| BioLife Solutions (BLFS) | United States | $1.128B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.075B | 24.19 |
| Kestra Medical Technologies (KMTS) | United States | $1.001B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.989B | 12.64 |
| InMode (INMD) | Israel | $0.903B | 9.10 |
| Evolus (EOLS) | United States | $0.660B | 0.00 |
| CeriBell (CBLL) | United States | $0.642B | 0.00 |
| Owens & Minor (OMI) | United States | $0.606B | 5.03 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.581B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.554B | 0.00 |
| Valneva SE (VALN) | France | $0.534B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.429B | 0.00 |
| Surmodics (SRDX) | United States | $0.415B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.359B | 13.21 |
| SNDL (SNDL) | Canada | $0.349B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.340B | 60.40 |
| Canopy Growth (CGC) | Canada | $0.289B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.283B | 0.00 |
| Cerus (CERS) | United States | $0.271B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.268B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.50 |
| ZimVie (ZIMV) | United States | $0.265B | 12.06 |
| Cresco Labs (CRLBF) | United States | $0.261B | 0.00 |
| Quanterix (QTRX) | United States | $0.259B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.257B | 0.00 |
| Brainsway (BWAY) | Israel | $0.222B | 58.65 |
| Biote (BTMD) | United States | $0.220B | 6.18 |
| OraSure Technologies (OSUR) | United States | $0.218B | 0.00 |
| Omeros (OMER) | United States | $0.212B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.199B | 0.00 |
| Organigram Global (OGI) | Canada | $0.197B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.185B | 15.09 |
| Verano Holdings (VRNOF) | United States | $0.183B | 0.00 |
| Exagen (XGN) | United States | $0.155B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.141B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.130B | 16.05 |
| Jin Medical (ZJYL) | China | $0.108B | 0.00 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.61 |
| TerrAscend (TSNDF) | Canada | $0.078B | 0.00 |
| Agape ATP (ATPC) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Apyx Medical (APYX) | United States | $0.067B | 0.00 |
| Zynex (ZYXI) | United States | $0.062B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 54.21 |
| United-Guardian (UG) | United States | $0.038B | 13.18 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.020B | 0.00 |
| Safety Shot (SHOT) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.014B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |